Feasibility of the inhibitor development for SARS-CoV-2: a systematic approach for drug design.

Paxlovid (nirmatrelvir/ritonavir) - Pfizer

http://www.ncbi.nlm.nih.gov/pubmed/41313484

Dazhi Cheng; Dongling Hu; Guangzhou Sun; Jianping Hu; Quanshan Shi; Wentong Yu; Xiaodong Shi; Xinru Yue; Yu Jiang; Yuting Song

Nov 28, 2025